Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 17, 2003. The report discloses the grant of awards and options to senior executives, including executive directors, under the GlaxoSmithKline Performance Share Plan and the GlaxoSmithKline Share Option Plan on December 15, 2003.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation structures and specific grant details rather than consolidated financial results.
Material Changes and Grant Details
The primary material event is the grant of equity-based compensation on December 15, 2003, with performance periods commencing January 1, 2004.
- Performance Share Plan:
- Measurement Period: Three years (January 1, 2004 to December 31, 2006).
- Condition: Total Shareholder Return (TSR) relative to 14 comparator companies (including Pfizer, Merck, and AstraZeneca).
- Vesting Thresholds: No vesting below 8th position; 100% vesting for 1st or 2nd position.
- Target Awards (Executive Directors):
- Dr. J-P Garnier: Up to 200,000 ADSs (1st/2nd position).
- Mr. J.D. Coombe: Up to 120,000 Shares (1st/2nd position).
- Share Option Plan:
- Subscription Price: £12.70 per share (US$44.57 per ADS).
- Measurement Period: Initial three-year period (2004-2006) with an extended period option (2004-2007).
- Condition: Compound annual increase in Earnings Per Share (EPS) must exceed the Retail Prices Index (RPI) by at least 3%.
- Vesting Thresholds: 50% vesting at RPI+3%; 100% vesting at RPI+5% or more.
- Target Options (Executive Directors):
- Dr. J-P Garnier: Up to 460,000 ADSs (RPI+5% or more).
- Mr. J.D. Coombe: Up to 276,000 Shares (RPI+5% or more).
Guidance, Outlook, and Risks
The filing does not contain financial guidance, general outlook, or management commentary on business operations. The primary risk disclosed relates to the vesting conditions of the executive awards, which are contingent on specific performance metrics (TSR ranking and EPS growth relative to inflation). If performance targets are not met, awards may lapse or vest at reduced levels.
Key Facts for Investor Verification
- Verify the current market price of GSK shares and ADSs against the option subscription price of £12.70 (US$44.57) to assess the intrinsic value of the granted options.
- Monitor GSK's Total Shareholder Return (TSR) performance relative to the specified comparator group (Abbott, AstraZeneca, Pfizer, etc.) for the 2004-2006 period.
- Track the company's Earnings Per Share (EPS) growth rate against the Retail Prices Index (RPI) to determine vesting eligibility for the Share Option Plan.
- Note that one ADS represents two ordinary shares when calculating total potential equity dilution.